StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $6.92 | $7.10 | +2.60% | 0.1M |
| 05-12 | $7.06 | $7.03 | -0.42% | 0.1M |
| 05-13 | $6.99 | $6.77 | -3.15% | 0.1M |
| 05-14 | $7.20 | $9.24 | +28.33% | 2.3M |
| 05-15 | $9.29 | $9.75 | +4.95% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|
Revenue | $23.78M | $1.77M |
Operating Income | $-12.77M | $-22.59M |
Net Income | $-16.05M | $-23.71M |
EPS (Diluted) | $-0.60 | $-0.90 |
Total Assets | $26.86M | $26.94M |
Total Liabilities | $38.49M | $29.51M |
Cash & Equivalents | $13.27M | $23.77M |
Free Cash Flow OCF − CapEx | Not available | Not available |
Shares Outstanding | 27.03M | 26.36M |
No sell-side coverage available for FENC.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for FENC.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.